A new standard of care for patients with pancreatic cancer Wednesday, January 09, 2019 The results of the Unicancer and the Canadian Cancer Trials Group (CCTG) PRODIGE 24 | CCTG PA.6 study have been published in the New England Journal of Medicine. The practice changing results indicate a significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy compared to the current standard treatment with gemcitabine From April 2012 to October 2016, 77 hospitals in France and Canada enrolled 493 post-operative pancreatic ductal adenocarcinoma patients in the PRODIGE 24 | CCTG PA.6 study. This was achieved through the collaboration of three French research groups organized under the umbrella of the PRODIGE Intergroup: Unicancer Gastrointestinal (UCGI), la Fédération Francophone de Cancérologie Digestive (FFCD) and the Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), and the Canadian Cancer Trials Group (CCTG). Find out more: PRODIGE 24 / CCTG PA.6 study
